This year's class of 15 young executives is deeply of the moment, with assignments that include advancing therapies against
hepatitis C, building new cell-based platforms in regenerative medicine, creating new businesses beyond a protected home base,
restructuring the supply chain to accommodate a new generation of complex biologics, and transforming raw data into "news
I can use" analytics. The emotional viscera that binds all is a commitment to the patient. Despite those legions of lawyers,
accountants, bankers, and regulators—none of whom made the list this year—pharma remains at heart a people business.
And the Leaders Are...
(In alphabetical order)
Joerg Ahlgrimm, VP of Operations, Baxter BioScience
Jenise Doutsas, Global Strategic Lead, Fertility, Ferring Pharmaceuticals
Brian Goff, Global Franchise Head, Hemophilia, Baxter Healthcare
Ian Harris, Senior Director and Platform Leader, Cell Therapy, Janssen Research & Development
Susanne Heinzinger, Executive Director of Product Strategy and Alliance Management, Achillion Pharmaceuticals
Michael Injaychock, Director, Marketing Innovation, Research and Commercial Analytics, Eli Lilly & Co.
Sachin Jain, Chief Medical Information and Innovation Officer, Merck & Co.
Arnaud Lesegretain, Vice President, Global Brand Development, Eli Lilly & Co.
Tom McDonnell, Vice President, Product Strategy Lead—Neuroscience, Shire Pharmaceuticals
Jamey Millar, VP Oncology Business Unit Head, GlaxoSmithKline
António Portela, CEO, Bial
Alexsey Repik, Founder and Chairman of the Board, R-Pharm
Monica Tellado, VP, US commercial operations. Gilead Sciences
Hayden Thomas, VP, formulation development, Vertex Pharmaceuticals
Jocelyn Trokenheim, Head of Global Business Development Office and Strategy, Takeda Pharmaceuticals